CBRS17061 / EA1131 / Michelle Shayne
Research Question:
What are the good and bad effects of getting more treatment with capecitabine (i.e.
one of the usual approaches) compared to getting more treatment with a platinum-based
chemotherapy (cisplatin or carboplatin) after surgery?
Basic Study Information
Purpose:
This randomized phase III trial studies how well cisplatin or carboplatin (platinum
based chemotherapy) works compared to capecitabine in treating patients with remaining
(residual) basal-like triple-negative breast cancer following chemotherapy after surgery
(neoadjuvant). Drugs used in chemotherapy, such as cisplatin, carboplatin and capecitabine,
work in different ways to stop the growth of tumor cells, either by killing the cells,
by stopping them from dividing, or by stopping them from spreading. It is not yet
known whether cisplatin or carboplatin is more effective than capecitabine in treating
patients with residual triple negative basal-like breast cancer.
Location: University of Rochester Medical Center
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02445391?term=ea1131&rank=1
Study Reference #: CBRS17061
Lead Researcher (Principal Investigator)
Lead Researcher:
Michelle Shayne, MD
Study Contact Information
Study Coordinator: Amber Johnson
Email: amber_johnson@urmc.rochester.edu
Additional Study Details
Learn More About These Conditions
More information about Breast Cancer
Trial Not Found
The study you are looking for is not active at this time.
Return to Search